乳糜泻药物市场：按药物、类型、适应症和最终用户划分 - 全球预测 2025-2030

乳糜泻治疗市场2023年估值为14.2亿美元，预计到2024年将达到15.6亿美元，复合年增长率为10.59%，预计到2030年将达到28.7亿美元。

乳糜泻药物市场研究将分析用于乳糜泻潜在管理和治疗的药物，乳糜泻是一种自体免疫疾病，小肠因摄取麸质而受损。范围包括正在开发的用于缓解症状、促进黏膜癒合或免疫调节的药物。这些药物的需求是由越来越多的乳糜泻患者、对无麸质生活方式的认识不断增强以及严格的无麸质饮食之外的未满足的需求所推动的。主要用途包括缓解症状的药物和免疫调节疗法。最终用途包括医院、研究机构和专科诊所。

市场成长受到医疗保健支出增加、生物技术进步以及患者和医生意识提高的影响。然而，对非饮食疗法的高需求提供了巨大的机会。製药公司可以利用创新配方和联合治疗。透过增加研发投资并透过与监管机构的伙伴关係加快医药品认证过程可以增加市场潜力。挑战包括严格的监管障碍、药物开发的高成本以及证明新治疗方法的长期疗效和安全性的综合临床试验资料有限。此外，自体免疫疾病固有的病理生理学复杂性也为药物设计带来了复杂性。

为了实现成长，创新应着重于个人化医疗方法，探索治疗药物与遗传因素之间的相互作用，并透过口服生技药品等替代药物传递系统来提高患者的依从性。富有洞察力的消费者资料分析可以将研究和开发指导到特定的亚组，从而可能改变标准治疗方法。该市场竞争激烈，但未来性，随着公司寻求投资组合多元化并利用生物技术的进步，预计合併和联盟将会增加。公司应积极监测监管趋势，并考虑建立策略联盟，整合基因组学和药物输送系统等新技术，以加速药物开发平臺。在不断变化的市场动态中，解决负担能力和获取问题对于实现更广泛的采用和永续仍然至关重要。

市场动态：揭示快速发展的乳糜泻药物市场的关键市场洞察

乳糜泻药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

• 市场驱动因素
  • 乳糜泻盛行率增加
  • 对含麸质即食包装食品的依赖增加
  • 政府和私人组织增加对乳糜泻认识的支持
• 市场限制因素
  • 治疗选择有限
• 市场机会
  • 活性化研发活动，引进先进的乳糜泻治疗药物
  • 医疗保健领域的技术进步与现代化
• 市场挑战
  • 政府对药品核准的严格规定

波特五力：驾驭乳糜泻药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解乳糜泻药物市场的外部影响

外部宏观环境因素在塑造乳糜泻治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解乳糜泻治疗药物市场的竞争状况

对腹腔疾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵乳糜泻药物市场供应商的绩效评估

FPNV 定位矩阵是评估乳糜泻药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划乳糜泻药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对乳糜泻治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 乳糜泻盛行率增加
    • 食品麸质的食品的依赖增加
    • 增加政府和私部门对乳糜泻认识的支持
  • 抑制因素
    • 治疗选择有限
  • 机会
    • 活性化研发活动以引进先进的乳糜泻治疗方法
    • 医疗保健领域的技术进步与现代化
  • 任务
    • 政府对药品核准的严格规定
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章 乳糜泻药物治疗市场

• 一线治疗
• 二线治疗

第七章乳糜泻药物市场：按类型

• 类固醇和免疫抑制剂
• 治疗性疫苗
• 维生素和营养食品

第八章乳糜泻药物市场（按适应症）

• 厌食症
• 腹胀
• 腹泻
• 扩张
• 疲劳
• 气体

第九章乳糜泻药物市场：依最终用户分类

• 临床研究组织
• 医院/诊所
• 研究/学术机构

第10章美洲乳糜泻药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十一章亚太乳糜泻药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十二章欧洲、中东和非洲乳糜泻药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十三章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• AbbVie Inc.
• Adaptive Biotechnologies Corp.
• Almirall SA
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• AMYRA Biotech AG
• Artielle Immunotherapeutics Inc.
• BioLineRx Ltd.
• Bristol Myers Squibb Company
• Calypso Biotech SA
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Inovera Bioscience
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Precigen Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Vactech Oy
• Zedira GmbH

The Celiac Disease Drugs Market was valued at USD 1.42 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 10.59%, to USD 2.87 billion by 2030.

Celiac Disease Drugs market research involves analyzing pharmaceuticals aimed at managing and potentially treating Celiac disease, an autoimmune disorder where gluten ingestion damages the small intestine. The scope covers drugs that either alleviate symptoms, promote mucosal healing, or are in development for immune modulation. The necessity for these drugs is driven by the increasing prevalence of diagnosed Celiac cases, expanding gluten-free lifestyle awareness, and the unmet need beyond a strict gluten-free diet. Key applications include pharmaceuticals for symptomatic relief and immune modulation therapies. End-use scopes involve hospitals, research institutions, and specialty clinics.

Market growth is influenced by rising healthcare expenditures, advancements in biotechnology, and heightened patient and physician awareness. However, substantial opportunities lie in the high demand for non-dietary therapeutics. Pharmaceutical companies can capitalize on innovative drug formulations and combination therapies. Expanding R&D investments and expediting drug approval processes through collaborative partnerships with regulatory authorities could enhance market potential. Challenges include stringent regulatory hurdles, high costs of drug development, and limited comprehensive clinical trial data demonstrating long-term efficacy and safety of emerging treatments. Additionally, the inherent complexity of autoimmune pathophysiology poses complications in drug design.

For growth, innovation should focus on personalized medicine approaches, exploring genetic component interactions with therapeutics, and enhancing patient compliance through alternative drug delivery systems such as oral biologics. Insightful consumer data analytics could redirect R&D towards specific subgroups, potentially changing standard care practices. The market's nature is competitive yet promising, with increased mergers and partnerships anticipated as firms strive to diversify portfolios and leverage biotechnological advancements. Businesses should actively monitor regulatory trends and consider strategic alliances to integrate emerging technologies like genomics and drug delivery systems to accelerate drug development pipelines. Addressing affordability and access remains crucial for wider adoption and sustainability in evolving market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Celiac Disease Drugs Market

The Celiac Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in prevalence of celiac disease
  • Rising dependence of gluten containing and ready-to-eat packaged food
  • Increase government and private organizations support towards celiac disease awareness
• Market Restraints
  • Restricted availability of treatment options
• Market Opportunities
  • Rising R&D activities to introduce advanced celiac disease drugs
  • Technological advancements and increasing modernization in the healthcare sector
• Market Challenges
  • Strict government regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Celiac Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Celiac Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Celiac Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Celiac Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Celiac Disease Drugs Market

A detailed market share analysis in the Celiac Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Celiac Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Celiac Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Celiac Disease Drugs Market

A strategic analysis of the Celiac Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Celiac Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., Amneal Pharmaceuticals LLC, AMYRA Biotech AG, Artielle Immunotherapeutics Inc., BioLineRx Ltd., Bristol Myers Squibb Company, Calypso Biotech SA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Inovera Bioscience, Johnson & Johnson Services, Inc, Pfizer Inc., Precigen Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., Vactech Oy, and Zedira GmbH.

Market Segmentation & Coverage

This research report categorizes the Celiac Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across First Line of Treatment and Second Line of Treatment.
• Based on Type, market is studied across Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, and Vitamins & Dietary Supplements.
• Based on Indication, market is studied across Anorexia, Bloating, Diarrhea, Distension, Fatigue, and Gas.
• Based on End-User, market is studied across Clinical Research Organizations, Hospitals & Clinics, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in prevalence of celiac disease
    • 5.1.1.2. Rising dependence of gluten containing and ready-to-eat packaged food
    • 5.1.1.3. Increase government and private organizations support towards celiac disease awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Restricted availability of treatment options
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising R&D activities to introduce advanced celiac disease drugs
    • 5.1.3.2. Technological advancements and increasing modernization in the healthcare sector
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulations for drug approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Celiac Disease Drugs Market, by Drug

• 6.1. Introduction
• 6.2. First Line of Treatment
• 6.3. Second Line of Treatment

7. Celiac Disease Drugs Market, by Type

• 7.1. Introduction
• 7.2. Steroids & Immunosuppressive Drugs
• 7.3. Therapeutic Vaccines
• 7.4. Vitamins & Dietary Supplements

8. Celiac Disease Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Anorexia
• 8.3. Bloating
• 8.4. Diarrhea
• 8.5. Distension
• 8.6. Fatigue
• 8.7. Gas

9. Celiac Disease Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Clinical Research Organizations
• 9.3. Hospitals & Clinics
• 9.4. Research & Academic Institutes

10. Americas Celiac Disease Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Celiac Disease Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Celiac Disease Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adaptive Biotechnologies Corp.
• 3. Almirall SA
• 4. Amgen Inc.
• 5. Amneal Pharmaceuticals LLC
• 6. AMYRA Biotech AG
• 7. Artielle Immunotherapeutics Inc.
• 8. BioLineRx Ltd.
• 9. Bristol Myers Squibb Company
• 10. Calypso Biotech SA
• 11. GlaxoSmithKline PLC
• 12. Glenmark Pharmaceuticals Ltd.
• 13. Inovera Bioscience
• 14. Johnson & Johnson Services, Inc
• 15. Pfizer Inc.
• 16. Precigen Inc.
• 17. Sanofi S.A.
• 18. Takeda Pharmaceutical Co. Ltd.
• 19. Vactech Oy
• 20. Zedira GmbH

LIST OF FIGURES

• FIGURE 1. CELIAC DISEASE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CELIAC DISEASE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELIAC DISEASE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FIRST LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SECOND LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY STEROIDS & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY VITAMINS & DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ANOREXIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BLOATING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FATIGUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023